UPDATE : Friday, August 23, 2019
상단여백
‘Medytox got review suspension in China only once’
Korean botulinum toxin maker Medytox said the Chinese regulator ordered the...
by Jeong Sae-im  |  2019-06-11 10:50
라인
[ASCO 2019] Imfinzi 1st IO to report 3-year OS in unresectable stage III NSCLC
Chicago, Ill -- AstraZeneca‘s Imfinzi (Ingredient: durvalumab) has demonstr...
by Lee Han-soo, KBR Correspondent  |  2019-06-11 08:00
라인
SCM, T&R to develop tissue regeneration, therapy products
SCM Life Science and T&R Biofab have agreed to collaborate on the research ...
by Lee Han-soo  |  2019-06-10 17:50
라인
Regulator OKs AstraZeneca's Fasenra as additional therapy for severe asthma
AstraZeneca's Fasenra (ingredient: benralizumab) gained approval as an ...
by Lee Han-soo  |  2019-06-10 17:10
라인
CJ HealthCare to invest ₩100 billion in new IV fluid factory
CJ HealthCare, a subsidiary of Kolmar Korea, said Monday it would invest 10...
by Jeong Sae-im  |  2019-06-10 16:17
라인
Hanmi unveils strong pipeline candidates in US diabetes meet
Hanmi Pharmaceutical said that it has confirmed its global competitiveness ...
by Lee Han-soo  |  2019-06-10 15:07
라인
Medytox’ botulinum toxin may face approval delay in China
Korean botulinum toxin maker Medytox may likely suffer a delay in Chinese r...
by Jeong Sae-im  |  2019-06-10 13:55
라인
Daewoong joins fray to develop rheumatoid arthritis drug
Daewoong Pharmaceutical said it has begun developing a rheumatoid arthritis...
by Lee Hye-seon  |  2019-06-07 11:29
라인
[ASCO 2019] 'Ibrance brings hopes to neglected premenopausal breast cancer patients'
CHICAGO, Ill. -- A Korean study has shown that Pfizer's Ibrance extends...
by Lee Han-soo, KBR Corresponden  |  2019-06-05 11:33
라인
[ASCO 2019]'Belvarafenib confirms efficacy for solid cancer without approved treatment'
CHICAGO, Ill. -- Belvarafenib, developed by Hanmi Pharmaceutical, has demon...
by Lee Han-soo, KBR Correspondent  |  2019-06-05 11:29
라인
FDA OKs phase-1 trial for Yuhan’s investigational lung cancer drug
Yuhan Corp. is gearing up to develop a new lung cancer drug Lazertinib (YH2...
by Jeong Sae-im  |  2019-06-04 14:21
라인
[ASCO 2019] ‘POLO study opens a new era for treating pancreatic cancer patients’
CHICAGO, Ill. -- AstraZeneca and MSD, also known as Merck & Co. inside the ...
by Lee Han-soo, KBR corresponden  |  2019-06-03 16:18
라인
[ASCO 2019]Novartis’ Kisqali aims to make comeback with new trial results
CHICAGO, Ill. -- Novartis Kisqali, a cyclin-dependent kinase (CDK) 4/6 inhi...
by Lee Han-soo, KBR correspondent  |  2019-06-03 13:41
라인
[ASCO 2019]Korea expanding presence in global oncology field
CHICAGO, Ill. -- American Society of Clinical Oncology (ASCO) 2019 kicked o...
by Lee Han-soo, KBR correspondent  |  2019-06-03 11:17
라인
[ASCO 2019]Roche CEO unveils his company’s future direction at ASCO 2019
CHICAGO, Ill. -- Roche Pharmaceuticals is one of is the largest healthcare ...
by Lee Han-soo, KBR correspondent  |  2019-06-03 11:09
라인
[ASCO 2019]'Asia vital region for Roche’
CHICAGO, Ill. -- The American Society of Clinical Oncology (ASCO) is one of...
by Lee Han-soo, KBR correspondent  |  2019-06-03 11:01
라인
Hanmi’s hypertension drug was effective in phase-4 study 
Hanmi Pharmaceutical’s new combination drug Amosartan (losartan/amlodipine)...
by Jeong Sae-im  |  2019-05-31 16:05
라인
AbbVie’s chronic lymphocytic leukemia drug wins Korean license
AbbVie Korea said it obtained the Ministry of Food and Drug Safety’s approv...
by Park Gi-taek  |  2019-05-30 15:14
라인
HIV prevention pill to get insurance benefit in Korea
The local medical community is likely to use a drug to prevent HIV infectio...
by Kim Yun-mi  |  2019-05-30 13:25
라인
Daiichi Sankyo to co-promote Daewoong's hypertension treatment
Daiichi Sankyo Korea has signed an agreement with Daewoong to co-promote Ol...
by Lee Han-soo  |  2019-05-29 14:50
여백
여백
여백
Back to Top